In a press release, Target RWE detailed insights from its dermatology-specific, real-world evidence registry, TARGET-DERM. The registry—which collected data from over 4,000 patients with immune-mediated inflammatory skin diseases, including 3,200 patients with atopic dermatitis, 700 patients with hidradenitis suppurativa, 350 patients with alopecia areata, and those with chronic spontaneous urticaria—was designed to help researchers better understand autoimmune conditions of the skin and develop novel therapeutics.
In a recent study—published by Abuabara et al in the Journal of the American Academy of Dermatology—researchers used TARGET-DERM data to determine that non-Hispanic White patients and older patients with atopic dermatitis highly impacting their quality of life were more likely to receive systemic treatments compared with other patient populations.
Additionally, Target RWE revealed that it has collected and stored a biorepository of over 150,000 biospecimens from whole blood, serum, plasma, saliva, tissue, and tape-strip samples—and continues to aggregate health data from patient outcomes, surveys, and questionnaires. “It is our hope that this research can better inform how [skin] conditions are approached and ultimately improve the lives of the millions of [patients] who suffer from them,” concluded Emma Guttman-Yassky, MD, PhD, the Waldman Professor and System Chair of Dermatology and Clinical Immunology at the Icahn School of Medicine at Mount Sinai, and Co-Chair of the TARGET-DERM Atopic Dermatitis Steering Committee.